Diasorin shoots in Piazza Affari after the agreement for the acquisition of the American Luminex Corporation. The stock of the diagnostics group, after failing to make a price in the first few minutes of trading, marks a jump of 8.74% € 151.80 and after hitting a maximum of € 155.5. The Italian group offers Luminex a cash price of $ 37 per share, equal to an equity value and an enterprise value of approximately $ 1.8 billion.
Yesterday the Italian group announced the acquisition of Luminex Corporation for a cash price of $ 37 per share and a total value of approximately $ 1.8 billion. The agreed price per share represented a premium of around 23.1% compared to the closing price as of February 24, 2021 (i.e. the day before rumors about the possible sale of Luminex were leaked) and a premium of around 30 , 6% and approximately 47.5% of the volume-weighted average price for the 30 and 90-day period prior to February 24, 2021, respectively.
Luminex develops, manufactures and sells proprietary technologies and biological examination products with various applications in the diagnostic and life science industries. With over 900 customers, it is an important player in the molecular diagnostics market. the company thus becomes complementary to DiaSorin’s business. The acquisition will allow access to Luminex applications in the life science sector, strengthening DiaSorin’s link with academic and scientific research.